Interactions between aluminum-hydroxide(aluminum hydroxide) and Amprenavir (amprenavir)
aluminum hydroxide and amprenavir (Moderate Drug-Drug)
ADJUST DOSING INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of amprenavir and reduce its concentrations in plasma. Amprenavir solubility decreases with increasing pH, thus reduction in gastric acidity may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance. In contrast, the prodrug fosamprenavir appears to be less affected by antacids. Administration of a single 1400 mg dose with 30 mL of antacid (Maalox TC) resulted in decreased peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of amprenavir by 35% and 18%, respectively. However, trough plasma concentration (Cmin) increased by 14%.
MANAGEMENT: Amprenavir should be administered at least 1 hour before or after antacids or other oral preparations containing antacids (e.g., didanosine buffered tablets or pediatric oral solution).
